In 2021, the FDA approved Novo Nordisk's Wegovy, a slight reformulation of Ozempic designed specifically for weight loss, which drove a huge spike in public awareness of GLP-1 agonists
What's the continuity-of-care plan if compounded GLP-1 availability changes due to FDA regulatory action
For mechanistic context behind these numbers, see the Retatrutide Research Guide and the GLP-1 Peptides Comparison Guide.
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout References Zelniker, T
doi: 10.1016/j.amepre.2016.07.033
It helps patients overcome biological barriers to weight loss, such as persistent hunger and cravings
